Pharmicell Co.,Ltd. Logo

Pharmicell Co.,Ltd.

A biopharmaceutical company specializing in stem cell therapies and fine chemicals.

005690 | KO

Overview

Corporate Details

ISIN(s):
KR7005690003
LEI:
Country:
South Korea
Address:
서울특별시 강남구 언주로 874 (신사동, 쌍봉빌딩 7층), 강남구

Description

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-21 00:00
단일판매ㆍ공급계약체결
Korean 7.6 KB
2025-08-13 00:00
[기재정정]사업보고서 (2024.12)
Korean 1.0 MB
2025-08-13 00:00
반기보고서 (2025.06)
Korean 779.0 KB
2025-07-15 00:00
주식등의대량보유상황보고서(일반)
Korean 110.2 KB
2025-07-08 00:00
기업설명회(IR)개최(안내공시)
Korean 6.1 KB
2025-05-08 00:00
분기보고서 (2025.03)
Korean 785.5 KB
2025-04-30 00:00
단일판매ㆍ공급계약체결
Korean 7.6 KB
2025-04-30 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-30 00:00
최대주주등소유주식변동신고서
Korean 32.6 KB
2025-04-29 00:00
주식등의대량보유상황보고서(일반)
Korean 111.8 KB
2025-04-22 00:00
단일판매ㆍ공급계약체결
Korean 7.6 KB
2025-04-01 00:00
주식등의대량보유상황보고서(일반)
Korean 118.0 KB
2025-04-01 00:00
최대주주등소유주식변동신고서
Korean 32.6 KB
2025-03-26 00:00
정기주주총회결과
Korean 28.9 KB
2025-03-26 00:00
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.0 KB

Automate Your Workflow. Get a real-time feed of all Pharmicell Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharmicell Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharmicell Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.